

Drug Utilization Review (DUR) Committee

January 17th 2014 Minutes

Members Present

Robin Cooke, PharmD, CGP
Jenny Love, MD
John Pappenheim, MD (*telephonic*)
Maggi Rader, CNM
Greg Salard, MD
Chuck Semling, PharmD
Chad Hope, PharmD (DHSS)

Members Absent/Excused

Non-Members Present

Erin Narus, PharmD (Magellan)

Meeting started at approximately 1:10pm; attendance was taken
Teleconference access available

Welcome

Review of minutes from November 15, 2013 meeting (Approved)

Review of agenda for changes

ProDUR

- Proposed Prior Authorization Ketoconazole (oral)
 - Safety concerns surrounding the use of ketoconazole prompted prior authorization criteria for Ketoconazole (oral) tablets
 - Ketoconazole restricted from first line usage and will not be approved for the treatment of fungal meningitis due to poor penetration into the cerebrospinal fluid

APPROVED, PASSED WITH ONE ABSTENTION

- Proposed Prior Authorization – Vimovo[®] (naproxen/esomeprazole magnesium)
 - Vimovo is a fixed dose combination product containing a PPI and NSAID
 - Vimovo is restricted to use in FDA approved indications and only after treatment failure with two separate medications and a trial combination of a generic PPI and NSAID.
 - Vimovo is restricted to 2 doses per day.

APPROVED, UNANIMOUS

- Proposed Prior Authorization – Diclegis[®] (doxylamine/pyridoxine)
 - Diclegis is a fixed dose combination product containing an antihistamine and a Vitamin B6 analog
 - Diclegis is restricted to its FDA approved indication of treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
 - Diclegis is restricted to 4 doses per day.

APPROVED, UNANIMOUS

- Proposed Prior Authorization – Vecamyl™ (mecylamine)
 - Vecamyl is restricted to its FDA approved indication of the management of moderately severe to severe essential hypertension and uncomplicated cases of malignant hypertension.
 - Vecamyl approval requires failure of at least 6 classes of medications within the last 12 months with documented history of failure to achieve blood pressure goals using maximum tolerated doses.
 - Vecamyl will not be approved if the patient has any contraindications to the drug.
 - Vecamyl is restricted to 10 doses per day.

APPROVED, UNANIMOUS

- Proposed Prior Authorization – Venlafaxine ER tablets
 - Venlafaxine ER tablet approval requires failure of trial of venlafaxine ER cap and letter of medical necessity

APPROVED, UNANIMOUS

- Proposed Quantity Limits
 - Quantity limits were proposed for the following medications:
Cymbalta, desvenlafaxine, venlafaxine ER caps and tabs, Khedezla, Fetzima, and Colcrys
 - Approved quantity limits can be found at:
http://dhss.alaska.gov/dhcs/Documents/pharmacy/pdfs/max_units_all.pdf

APPROVED, UNANIMOUS

- Interim Prior Authorization List Review – Removal
 - The following medications were reviewed for Interim PA list removal:
Desvenlafaxine ER, Prolensa drops, Osphena, Sod Sulfate-Sulfur, Simbrinza, Namenda XR, Zenzedi, Doryx DR, Nymalize

APPROVED, UNANIMOUS

- Interim Prior Authorization List Review – Move
 - The following medications were reviewed for Interim PA list removal and placing under new PA bucket criteria and QLs:
Cancer & Specialty – Afinitor tablets & DISPERZ, Mekinist, Tafinlar, Tobi Podhaler
Medications Reformulated – Zipsor, Liptruzet, Tretin-X
Topical Combos & New Topical Formulations – Topicort Spray

APPROVED, UNANIMOUS

Retrospective DUR

- Criteria reviewed: Concurrent use of simvastatin and amlodipine, increased risk of rhabdomyolysis.
- Case profiles were discussed as necessary for potential criteria letters to be sent out to physicians. Interventions discussed on profiles varied from polypharmacy, polyprovider, therapeutic duplication, over-utilization, high-dose, drug-drug interactions, candidates for possible “lock-ins”, and unnecessary care/duration. As part of the process, the information is evaluated from different perspectives; viewing as a prescriber or the other end as a pharmacist who dispenses the prescription.

Next Meeting

March 21, 2014 at 1:00pm

Meeting adjourned.